The upgrade from Equal-Weight to Overweight by a major financial institution like Wells Fargo, accompanied by a significant increase in the price target from $12 to $35, suggests a strong bullish outlook for Spyre Therapeutics. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.